| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Karen A Holbrook last filed a Form 4 in September 2017, as Director at TECH. Karen A Holbrook's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 914 shares of TECH. The TECH filings lean toward selling, a net 7,059 shares.
Karen A Holbrook has 5 Form 4 filings on record from October 2015 to September 2017, all as Director at Bio-Techne (TECH), 2015–2017.
The 8 reported transactions were 3 open-market sales, 2 stock awards, 2 option or other derivative awards and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $791K.
The largest open-market sale was 5,000 shares of TECH at an average $111.15 on May 25, 2017, about $556K.
Shares as reported in the last Form 4 for each company; the most recent is from September 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.